Gilead upgraded by Morgan Stanley on lenacapavir potential
Morgan Stanley has upgraded Gilead Sciences (NASDAQ:GILD) to overweight from equal weight, citing the company's HIV drug ...
Lenacapavir: The 'Breakthrough Of The Year' Drug For HIV Care
A significant breakthrough in treating the Human Immunodeficiency Virus (HIV) came recently with the US Federal Drug ...
HIV drug lenacapavir is a breakthrough in treating AIDS
The US drug administration has approved the use of the medication as an injection for use against the multidrug resistant ...
FDA approves lenacapavir for HIV treatment; Science journal hails it as 'breakthrough of the year'
In a major step forward in the fight against HIV/AIDS, the US Food and Drug Administration (FDA) has approved Lenacapavir, an ...
News Medical on MSN12h
HIV drug access remains a major challenge despite promising trial results
Promising new drugs to prevent and treat HIV have the potential to transform the response to the disease. But getting these ...
Armed robbery in Revesby4d
WHO Unveils New Lenacapavir, HIV Testing Guidelines
WHO is convening a Guideline Development Group (GDG) for the development of new guidelines on the use of injectable ...
Morgan Stanley upgrades Gilead on HIV treatment growth
Morgan Stanley upgraded Gilead Sciences Inc (NASDAQ:GILD) to "overweight" from "equal weight," raising its price target to $113 from $87 on HIV prevention drug Lenacapavir (PrEP) and next-gen HIV ...
devdiscourse11d
Revolutionary HIV Drug: Lenacapavir Signals New Hope
Lenacapavir, approved by the US FDA, presents a groundbreaking advancement in the battle against HIV. Developed by Gilead ...
SciDev1dOpinion
HIV drug access crisis persists despite trial success
Addressing stigma, inequity, and access to HIV innovations remains critical to progress in the global HIV response, says IAS ...
AMD downgraded, Nike upgraded: Wall Street's top analyst calls
Morgan Stanley upgraded Gilead (GILD) to Overweight from Equal Weight with a price target of $113, up from $87. The firm sees ...